Durham, United States
Xilis, founded in 2019, is pioneering in the Biotechnology and Pharmaceutical sectors with its cutting-edge technologies focused on drug discovery, development, and precision oncology.
The company is making strides with its next-generation ex-vivo technology which aims to accelerate and de-risk the drug development process from discovery phases to clinical trials. This innovation also enhances the precision of cancer therapy, promising more effective treatment plans and better patient outcomes.
Xilis recently secured a $19.00M late venture capital investment as of 01 April 2025, underscoring strong investor confidence in its potential to revolutionize the biotech space.
As it continues to develop its transformative technologies, Xilis stands out as a promising prospect for investors eyeing groundbreaking advancements in drug development and oncology. Although the specifics of its latest backers are not disclosed, the secured investment highlights its strategic market positioning and the trust it garners within the industry.
